The MAP strategy prevented no-reflow in 100% of STEMI patients undergoing percutaneous coronary intervention, achieving TIMI flow grade 2 or 3 with no deaths at 9 months.
Observational (n=71)
No
Does the 'MAP strategy' prevent no-reflow in patients with STEMI undergoing PCI?
The 'MAP strategy' combining thrombus aspiration, tirofiban, and prolonged balloon/stent inflation was safe and associated with no incidence of no-reflow in STEMI patients undergoing PCI.
'No-reflow' phenomenon is a common occurrence in percutaneous coronary intervention (PCI). A three-component 'MAP strategy' was designed to prevent no-reflow by addressing both intralesional and intraluminal thrombus in patients with ST-segment elevation myocardial infarction (STEMI). In this analysis, we observed Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 or 2 in all patients, with no incidence of no-reflow. Myocardial blush grade (MBG) 3 or 2 was observed in most (87.32%) patients. Left ventricular ejection fraction (LVEF) was improved, without any incidence of death up to 9-month follow-up. All patients safely tolerated the strategy-driven prolonged, 35-s inflation of the balloon/stent.
Potdar et al. (Tue,)はST上昇型心筋梗塞（STEMI）における観察研究（n=71）を実施しました。MAP戦略（最大吸引、補助的GP IIb/IIIa阻害剤、バルーン/ステント膨張の延長）がノーリフローの発生率（TIMIフローグレード0または1）に対して評価されました。MAP戦略は経皮的冠動脈インターベンションを受けたSTEMI患者のうち100％でノーリフローを防ぎ、9ヶ月で死亡率ゼロでTIMIフローグレード2または3を達成しました。